2022
- · JuneReports OriCAR-017 Phase I POLARIS study Data in Oral Presentation at ASCO 2022
- · MayOriCAR-017 Clinical Data Selected for Oral Presentation at EHA 2022 Congress
Selected in Shanghai Professional, Refined, Specialized, Novel Businesses List - · AprilCAR-T product candidate OriCAR-017 clinical data abstract selected for oral presentation at ASCO 2022
- · MarchAnnounced the appointment of Dr. Weidong Cui as Chief Technology Officer
2022
- · NovemberOricell and Cytiva Signs Strategic Cooperation Agreement at the 5th China International Import Expo
- · OctoberGPRC5D CAR-T receives Orphan Drug Designation from FDA
- · SeptemberReceives Implied License from NMPA for Ori-C101 IND Application
- · AugustRaises Over $120 Million in Series B Financing
2021
- · AugustOricell Therapeutics was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality
- · JuneThe first CAR-T cell product targeting liver cancer developed by OriCell Therapeutics made its debut at ASCO
- · MayOricell Medical Technology Co., Ltd. officially changed its name to "OriCell Therapeutics (Shanghai) Co., Ltd."
2021
- · DecemberOricell Therapeutics once again receives "High and New Technology Enterprise" recognition since November 2018
- · NovemberOricell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for poster presentation at the 2021 CSCO Annual Meeting
2020
- · DecemberReceived the A round of financing of 202.138 million, an investment led by SPINNOTEC, Zhangjiang Technology Venture Capital, and Yijing Capital, followed by Qiming Venture Partners and Osen Assets
Established the Shanghai Academician (Expert) Workstation< - · NovemberEstablished the Pudong New Area Enterprise Postdoctoral Research Workstation Substation
- · OctoberWon the first prize in the 13th "Zhangjiang Pharma Valley Cup" Biomedicine Experimental Skill Competition
- · JuneResponsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality
Reached a global development agreement regarding the independently-developed bispecific antibody with ANTENGENE (6996.HK), with a potential worth of 142 million USD
2019
- · DecemberReceived the pre-A round of exclusive funding from Qiming Venture Partners
2018
- · OctoberAttended the 2018 Chinese Conference on Translational Medicine and presented its independent R&D results in multiple fields
- · JuneResearch results for CAR-T in liver cancer were published in the authoritative journal Protein & Cell
- · MaySigned a strategic cooperation agreement with an emerging enterprise in the domestic CAR-T industry, Beijing Yimiaoshenzhou Medical Technology Co., Ltd.
2022
- · JuneReports OriCAR-017 Phase I POLARIS study Data in Oral Presentation at ASCO 2022
- · MayOriCAR-017 Clinical Data Selected for Oral Presentation at EHA 2022 Congress<br>Selected in Shanghai Professional, Refined, Specialized, Novel Businesses List
- · AprilCAR-T product candidate OriCAR-017 clinical data abstract selected for oral presentation at ASCO 2022
- · MarchAnnounced the appointment of Dr. Weidong Cui as Chief Technology Officer
2022
- · NovemberOricell and Cytiva Signs Strategic Cooperation Agreement at the 5th China International Import Expo
- · OctoberGPRC5D CAR-T receives Orphan Drug Designation from FDA
- · SeptemberReceives Implied License from NMPA for Ori-C101 IND Application
- · AugustRaises Over $120 Million in Series B Financing
2021
- · AugustOricell Therapeutics was the responsible unit for the biomedical technology support special project under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality
- · JuneThe first CAR-T cell product targeting liver cancer developed by OriCell Therapeutics made its debut at ASCO
- · MayOricell Medical Technology Co., Ltd. officially changed its name to "OriCell Therapeutics (Shanghai) Co., Ltd."
2021
- · DecemberOricell Therapeutics once again receives "High and New Technology Enterprise" recognition since November 2018
- · NovemberOricell Therapeutics' data from the first IIT in metastatic osteosarcoma to the lung was accepted for poster presentation at the 2021 CSCO Annual Meeting
2020
- · DecemberReceived the A round of financing of 202.138 million, an investment led by SPINNOTEC, Zhangjiang Technology Venture Capital, and Yijing Capital, followed by Qiming Venture Partners and Osen Assets<br>Established the Shanghai Academician (Expert) Workstation<
- · NovemberEstablished the Pudong New Area Enterprise Postdoctoral Research Workstation Substation
- · OctoberWon the first prize in the 13th "Zhangjiang Pharma Valley Cup" Biomedicine Experimental Skill Competition
- · JuneResponsible unit for the technology innovation funding project for small and medium-sized technology-based enterprises under the "Science and Technology Innovation Action Plan" of the Science and Technology Commission of Shanghai Municipality<br>Reached a global development agreement regarding the independently-developed bispecific antibody with ANTENGENE (6996.HK), with a potential worth of 142 million USD
2019
- · DecemberReceived the pre-A round of exclusive funding from Qiming Venture Partners
2018
- · OctoberAttended the 2018 Chinese Conference on Translational Medicine and presented its independent R&D results in multiple fields
- · JuneResearch results for CAR-T in liver cancer were published in the authoritative journal Protein & Cell
- · MaySigned a strategic cooperation agreement with an emerging enterprise in the domestic CAR-T industry, Beijing Yimiaoshenzhou Medical Technology Co., Ltd.